Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study Of Imatinib Mesylate And Bevacizumab In Patients With Advanced Melanoma And Other Advanced Cancers

Trial Profile

A Phase I/II Study Of Imatinib Mesylate And Bevacizumab In Patients With Advanced Melanoma And Other Advanced Cancers

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Imatinib (Primary)
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Apr 2008 Status changed from completed to in progress according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top